Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy
NCT05902962Phase 1Completed
- Sponsor
- PYC Therapeutics
- Start
- Apr 2023
- Primary completion
- Aug 2025
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VP-001 in retinitis pigmentosa type 11 (RP11), sponsored by PYC Therapeutics. Primary endpoint: Incidence, severity, and relatedness of treatment-emergent ocular adverse events and serious adverse events in the study eye at 48 weeks. Started Apr 2023; status: completed.
02
Drugs
VP-001
03
Conditions
retinitis pigmentosa type 11 (RP11)
Beyond the preview
Go deeper on NCT05902962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05902962.